Understanding side effects and quality of life for diverse patients using immune therapies for cancer.
Official title: Symptomatic Toxicities & Quality of Life among Diverse Individuals Receiving Immune Checkpoint Inhibitors for Metastatic Cancer.
Funded at University of Miami School of Medicine · NIH-11040016 · Data updated 2026-11-12
This study is looking at how different people with advanced cancer feel while getting immune checkpoint inhibitors, focusing on their side effects and quality of life, to help improve support and care for patients like you.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project start | February 1, 2025 |
| Project end | January 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $1,131,820 |
| NIH project number | 1R37CA288566-01A1 |
| Project ID | NIH-11040016 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with metastatic cancer who are being treated with immune checkpoint inhibitors.
✕Less likely to help
Patients not receiving immune checkpoint inhibitors or those with early-stage cancer may not benefit from this research.
What this research studies
This research investigates the side effects and overall quality of life experienced by patients from diverse backgrounds who are receiving immune checkpoint inhibitors for metastatic cancer. It aims to gather patient-reported outcomes to better understand the range of mild to severe toxicities associated with these treatments. By focusing on a well-characterized group of racially, ethnically, and socioeconomically diverse individuals, the study seeks to identify predictors of these toxicities and their impact on patients' lives. The findings could help improve care delivery and support for patients undergoing this type of cancer therapy.
Why it matters
Potential benefit: If successful, this research could lead to improved management of side effects and enhanced quality of life for cancer patients receiving immune therapies.
How similar studies have gone: Previous research has shown that understanding patient-reported outcomes can significantly enhance treatment strategies and patient care in oncology, indicating a promising approach in this area.
Where this research is happening
-
University of Miami School of Medicine
Coral Gables, United States Active
Researchers
- Principal investigator: Moreno, Patricia Ingrid — University of Miami School of Medicine
- Study coordinator: Moreno, Patricia Ingrid
Related research
Other NIH-funded projects on the same topics.
-
Symptoms and quality of life during immunotherapy for metastatic cancer
The team will track symptoms and day-to-day quality of life in people with metastatic cancer who are receiving immune checkpoint inhibitor treatments.
-
Understanding how immune checkpoint drugs can trigger inflammatory arthritis in cancer patients
This research looks at why some cancer patients develop inflammatory arthritis after PD-1 inhibitor therapy and what could be done to prevent it.
-
Gut bacteria that can make cancer immunotherapy less effective
This project will see if reducing chronic inflammation driven by certain gut bacteria can help immunotherapy work better for people whose cancers have stopped responding.
-
Decoding how NSCLC patients respond and react to immunotherapy through noninvasive blood tests and tumor samples
A study in people with non-small cell lung cancer will look at blood and tumor samples to understand why some patients benefit from immunotherapy and who might have serious side effects.
-
Understanding skin reactions from immune cancer drugs and how our body’s immune system reacts to them
This grant explores why some people develop severe skin reactions when treated with immune checkpoint inhibitors and aims to use patient data and tissue studies to improve care.
-
Targeting NNMT in the tumor environment to make immunotherapy work better
Aiming to boost cancer treatment by blocking NNMT in the tumor’s supportive tissue so immune therapies work more effectively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.